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ABSTRACT
Objectives: This study aimed to estimate the cost-effectiveness of an
extended (12 + 12 weeks) course of varenicline using the (Beneﬁts of
Smoking Cessation on Outcomes) BENESCO smoking cessation model.
Methods: Data on the efﬁcacy of 12 + 12 weeks varenicline therapy in
aiding smoking cessation were analyzed in conjunction with the efﬁcacy
data for 12 weeks of varenicline, bupropion, and placebo previously
included in the BENESCO model, by using a mixed treatment comparison.
This analysis provided updated efﬁcacy estimates for all the interventions,
and these were used to update the model to estimate the relative cost-
effectiveness of all smoking cessation interventions considered, now
including 12 + 12 weeks of varenicline.
Results: The updated 1-year abstinence estimates derived from the mixed
treatment comparison were, for 12 + 12 weeks of varenicline, 12 weeks of
varenicline, 12 weeks of bupropion, and 12 weeks of placebo, respectively:
27.7%, 22.9%, 15.9%, and 9.3%. The average cost of the course of
12 + 12 weeks of varenicline was estimated at $603.89, based on a
12-week course followed by a further 12 weeks for successful quitters.
Over all subjects’ lifetimes, 12 + 12 weeks of varenicline is less costly and
more effective than (dominates) all other strategies compared in the
updated BENESCO model, with the exception of 12 weeks of varenicline.
In this comparison, 12 + 12 weeks of varenicline is a very cost-effective
alternative to the 12-week course, with an incremental cost of less than
$1000 per quality-adjusted life year (QALY) gained.
Conclusions: A total of 12 weeks of varenicline followed by a further
12-week course for successful quitters is a highly cost-effective alternative
compared with currently available smoking cessation options.
Keywords: cost-effectiveness, extended course, maintenance therapy,
smoking cessation, varenicline.
Introduction
The consequences of smoking impose a global burden of mortal-
ity, morbidity, and cost [1]. Effective smoking cessation has been
cited as one of the most cost-effective interventions that are
possible within a health-care system because the gains in health
outcomes and economic beneﬁts are considerable [2].
A number of smoking cessation alternatives are available, but
the most recently approved of these, varenicline, has demon-
strated superior levels of smoking cessation efﬁcacy than any
existing alternative. Varenicline binds with high afﬁnity and
selectivity at the a4b2 neuronal nicotinic acetylcholine receptor,
where it acts as a partial agonist, resulting in a reduction in
craving for and withdrawal from nicotine.
Compared with placebo, nicotine replacement therapy (NRT)
and bupropion SR approximately double the odds of staying
abstinent 6 to 12 months after quitting [3,4], whereas varenicline
raises the odds of one-year abstinence by 2.5 to 3 times [5–7].
Previous health economic modeling has demonstrated that a
12-week course of varenicline is a highly cost-effective smoking
cessation intervention, dominating all other alternatives over the
lifetime time horizon [8]. The National Institute for Health and
Clinical Excellence has also endorsed the use of varenicline
within its licensed indication [9]. New data that support the use
of an extended course of varenicline are now available, with a
further 12 weeks of treatment in subjects who have successfully
quit after an initial 12 weeks of treatment [10]. This analysis
models the cost-effectiveness of this extended varenicline treat-
ment course in comparison with all currently available smoking
cessation alternatives.
Patients and Methods
The (Beneﬁts of Smoking Cessation on Outcomes)
BENESCO Model
The BENESCO model is a Markov model simulation of the
effects of various smoking cessation interventions in a population
of adult American smokers and has previously been published
[8]. The model is based on the earlier Health and Economic
Consequences of Smoking (HECOS) model [11]. The modeled
population is the 25% of smokers in the United States who are
assumed to make a single quit attempt. The size and demography
of this starting population were based on the 2004 census ﬁgures
[12] and published smoking rates [13] (11.9 million subjects
from 47.7 million adult smokers). The model allows a single
smoking quit attempt during the ﬁrst year, and no further
attempts may be made. Successful quitters have diminishing
chances of relapsing back to smoking each year in the model.
Relapse rates are independent of the initial smoking cessation
intervention used. The incidence of smoking-related morbidities
is modeled, with the diseases considered being lung cancer,
stroke, coronary heart disease (CHD), chronic obstructive pul-
monary disease (COPD), and asthma. Treatment costs for
smoking-related morbidities were drawn from literature [14–18],
and smoking cessation intervention costs were based on 2005 US
Red Book prices [19]. Utility values for the various model states
were also drawn from a variety of literature sources [20–27]. The
relative risks between smokers and nonsmokers of incidence and
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mortality from smoking-related morbidities are based on the
hazard ratios published by Thun from the Cancer Study (CPS) II
Study [28]. Direct costs, quality-adjusted life years (QALYs), and
life years are totaled in the model and discounted at 3% per year.
Incremental cost-effectiveness ratios (ICERs) in the form of incre-
mental cost per QALY gained and incremental cost per life year
gained are calculated over the time frames of 5, 10, and 20
years and the lifetime of the cohort. One-way and probabilistic
sensitivity analyses were conducted, with the probabilistic
analyses focusing on uncertainty in utility values, morbidity
treatment costs, and relative efﬁcacies of the smoking cessation
interventions.
Over 20 years, and also over the lifetime of all subjects, 12
weeks of treatment with varenicline was previously found to be
less costly and more effective (the dominant strategy) than the
other smoking cessation strategies considered in the BENESCO
model, namely, bupropion, NRT, placebo, and unaided cessation
[8]. Probabilistic and univariate sensitivity analyses appeared to
demonstrate that the underlying model was stable and that it was
most sensitive to the assumptions around effectiveness estimates
(1-year quit rates) and baseline utility values.
The model results were driven by the following underlying
behavior. Large numbers of subjects (25% of the smoking popu-
lation) attempting to quit in the ﬁrst year cause a large initial
treatment cost. Subsequently, the costs and outcomes are driven
by the relative effectiveness of the quitting strategy attempted.
After the ﬁrst year, subjects are either smokers (those who
relapsed or did not successfully quit) or successful quitters (those
who successfully quit and have avoided relapse). Smoking-
related morbidities may then occur at higher rates in the smoking
population. Consequently, smokers in the model may expect to
experience lesser life expectancy and quality of life (because of
morbidity and mortality) and incur more costs (because of mor-
bidity) than nonsmokers. Less successful smoking cessation inter-
ventions are therefore associated with lower life expectancy,
lower quality of life, and higher nontreatment costs.
New Evidence
A randomized, double-blind trial published in 2006 [10] exam-
ined the beneﬁts of 12 weeks of maintenance therapy with
varenicline (or placebo) in subjects who have successfully quit
after 12 weeks of initial open-label varenicline therapy. Subjects
were adult smokers (aged between 18 and 75 years) who smoked
an average of 10 or more cigarettes a day, who had not had an
abstinent period of over 3 months in the previous year, and were
motivated to quit.
In an initial, single-arm, open-label phase, 1927 subjects
received varenicline for 12 weeks. There were 717 patients who
relapsed to smoking by the end of the ﬁrst 12 weeks. The 1210
subjects who were abstinent entered into the randomized,
double-blind maintenance phase. The maintenance phase con-
sisted of 12 further weeks of treatment and follow-up for a
further 28 weeks, so that abstinence 52 weeks after initial cessa-
tion attempt could be assessed. There were 603 patients random-
ized to varenicline maintenance and 607 patients randomized to
placebo. After the follow-up at the end of the maintenance phase,
263 (43.6%) of the subjects receiving varenicline maintenance
therapy were conﬁrmed abstinent, compared with 224 (36.9%)
of those receiving placebo maintenance.
Updating the BENESCO Model
The BENESCO model was updated to include the 12 + 12 weeks
of varenicline as a further treatment option. The 12 + 12 weeks
was composed of 12 weeks of initial therapy with 1 mg vareni-
cline twice daily followed by 12 weeks of maintenance therapy,
again 1 mg twice daily. The maintenance therapy was only pro-
vided to those subjects who were successfully abstinent after the
initial 12 weeks of varenicline. This treatment strategy matched
the design of the new trial [10].
The data from the 12 + 12-week varenicline study [10] were
combined with the various efﬁcacy data used to inform the
original BENESCO model, within a mixed treatment comparison
[29]. This technique allows data from many studies with various
shared comparators to be combined to provide estimates of
comparative effect. These estimates were then used as the new
efﬁcacy ﬁgures to drive the BENESCO model.
The cost of the 12 + 12-week course of varenicline was also
calculated and added into the updated model. All subjects start-
ing a 12 + 12-week course of varenicline incur 12 weeks of costs
(covering one physician visit and 12 weeks of varenicline). Based
on the reported 12-week abstinence rates [10], 63% of subjects
will then commence a further 12 weeks of maintenance therapy
(another physician visit and a further 12 weeks of varenicline).
The cost of the 12 + 12-week course was therefore calculated as
two times the cost of the 12-week course for 63% of subjects and
one times the cost for the remainder.
Patient Population
The population modeled in the BENESCO model is based on the
2004 census ﬁgures for the United States [12]. Subjects included
are aged 18 or above and are split into age bands (18–34, 35–64,
and 65+) and by sex.
Smoking prevalence rates are taken from the 2005 National
Health Interview Survey report [13] and calculated for the age
and sex groupings.
The model assumes that 25% of all adult smokers will make
a quit attempt and that the attempt occurs at the start of the
model, so that the 1-year quit rates apply during the ﬁrst year of
the model.
Efﬁcacy Update Methodology
The smoking cessation strategies included as options within the
BENESCO model are varenicline, bupropion, NRT, and unaided
cessation.
The quit rates for each treatment other than NRT were esti-
mated by using mixed treatment comparison methods [29]. An
advantage of this approach is that efﬁcacy parameters for
placebo, bupropion, and varenicline treatments could be esti-
mated simultaneously from the randomized controlled trial
(RCT) data by using one internally consistent statistical model.
For treatments j = 1, . . . , J assessed in trials i = 1, . . . , I, the
number of patients who quit nij is assumed to follow a binomial
distribution according to the number of patients randomized to
that treatment arm Nij and a probability parameter pij (Equation
1):
n Bi Nij ij ij∼ , π( ) (1)
The quit log odds is modeled as the sum of a study random effect
mi and a study and treatment speciﬁc random effect dij, which may
be interpreted as a log odds ratio for treatment j in study i
(Equation 2).
log
π
π
μ δij
ij
i ij
1−
⎛
⎝⎜
⎞
⎠⎟ = + (2)
The study and treatment effect are assumed to arise from a
normal distribution with mean δ j. Here, we have data from three
trials (I = 3) and four treatments (J = 4), as shown in Table 1. We
210 Knight et al.
set di,1 = 0 for the identiﬁcation of all the parameters. The quit
rates for each treatment j are then estimated as μ δ+ j where μ is
the average study effect for studies with placebo arms.
The study providing efﬁcacy evidence for varenicline given
over 12 + 12 weeks was the two-stage study described earlier
[10]. The 52-week efﬁcacy of 12 weeks treatment with vareni-
cline from this study was calculated as the product of the efﬁcacy
from the ﬁrst 12 weeks varenicline treatment and the efﬁcacy
from the follow-up to 1 year of a subsequent 12 weeks of placebo
treatment: 23.2% (=1210 out of 1927 ¥ 224 out of 607). The
52-week efﬁcacy of 12 + 12 week varenicline was calculated as
the product of the efﬁcacy from the ﬁrst 12 weeks varenicline
treatment and the efﬁcacy from the follow-up to 1 year of the
subsequent 12 weeks of varenicline treatment: 27.4% (=1210 out
of 1927 ¥ 263 out of 603). For the purposes of the mixed treat-
ment comparison and so as not to overweight this study, these
efﬁcacy data were assumed to arise from 603 and 607 patients.
Results
Efﬁcacy Summary
The data used to drive the mixed treatment comparison of
varenicline, bupropion, and placebo are shown in Table 1. The
calculated 1-year quit rates for 12 weeks of varenicline and
bupropion are higher than the values used in the original
BENESCO model (22.9% vs. 22.4% for 12 weeks varenicline,
15.9% vs. 15.4% for 12 weeks bupropion). The changes in these
values are due to both the change in calculation method (mixed
treatment comparison compared with simple pooling of
numbers) as well as the inclusion of additional data on 12 weeks
of varenicline efﬁcacy from the extra included study.
The resulting updated 1-year quit rates used in the updated
BENESCO model, along with the pooled ﬁgures used in the
initial version of the model for comparison, are shown in Table 2.
The derivation of the efﬁcacy rate for NRT is unchanged from
the methodology used in the original BENESCO model: it is
calculated by using a published odds ratio from a meta-analysis
by Silagy et al. [3]. This ﬁgure (odds ratio 1.77, 95% conﬁdence
interval: 1.66, 1.88, P < 0.00001) is combined with the 1-year
quit rate estimated above for placebo to derive an estimate of the
1-year quit rate for NRT. The resulting estimate for NRT efﬁcacy
is shown in Table 2.
Costs Summary
The costs of the smoking cessation interventions are unchanged
from the values calculated and used in the original model. These
are reproduced in Table 2, alongside the average cost per quit
attempt for 12 + 12 weeks of varenicline, the new intervention
included in the model.
Summary Results
There are two sources of change to the results of the BENESCO
model. Firstly, the new treatment comparator (12 + 12 weeks of
varenicline) extends the tables of results by treatment. Secondly,
the updated efﬁcacy ﬁgures, now derived from the mixed treat-
ment comparison, causes all the results to change slightly from
their previously published values. General patterns and overall
conclusions regarding cost-effectiveness and time frames to
dominance are not changed.
Tables 3 and 4 show the summary results for the 12- and
12 + 12-week courses of varenicline as well as the 12-week
course of bupropion, NRT, and unaided cessation. Only the
varenicline (12 weeks) and bupropion per-treatment results are
different from those published in the original report [8], but
results for NRT and unaided cessation are presented again for
ease of comparison.
Summary ICERs
The incremental cost-effectiveness ratios estimated by the
updated BENESCO model are presented in Table 5. Over the
lifetime of all subjects in the model, 12 + 12 weeks of varenicline
is less costly and more effective than (dominates) all other strat-
egies compared in the updated BENESCO model, with the excep-
tion of 12 weeks of varenicline. In the case of this comparison,
12 + 12 weeks of varenicline is a very cost-effective alternative to
the 12-week course, with an incremental cost of less than $1000
per QALY gained.
Updated Probabilistic Sensitivity Analysis
As part of the update to the BENESCO model, the probabilistic
sensitivity analysis as deﬁned in the original model [8] was
extended to include 12 + 12 weeks of varenicline. A summary of
the results from 500-run simultaneous comparisons of 12 + 12
weeks of varenicline with the other smoking cessation treatments
included in the updated BENESCO model is presented in Table 6,
and the ﬁndings are consistent with those from the original
BENESCO model. The results suggest that the model is stable,
and 12 + 12 weeks of varenicline is acceptably cost-effective
(using a threshold of $30,000 per QALY gained) in at least 70%
of probabilistic runs, regardless of the comparator treatment.
Discussion
The ﬁndings of this extension to the BENESCO model are in
keeping with the ﬁndings of the original publication, namely, that
Table 1 Proportions and numbers of patients who had quit at 12 months
Reference Placebo (%) Varenicline (12 weeks) (%) Varenicline (12 + 12 weeks) (%) Bupropion (12 weeks) (%)
Tonstad [10]* — 23.2 (N = 603) 27.4 (N = 607) —
Jorenby [7] 10.3 (35 out of 341) 23.0 (79 out of 344) — 14.6 (50 out of 342)
Gonzalez [5] 8.4 (29 out of 344) 21.9 (77 out of 352) — 16.1 (53 out of 329)
*The sample sizes given for Tonstad et al. refer to the 1210 patients from this trial of 1927 patients whose smoking had not relapsed by the end of 12 weeks.
Table 2 Efﬁcacy assumptions (1-year quit rate) and costs of various
treatment courses used in the updated BENESCO model
Treatment
% Abstinent
at 1 year
Previous value
used in original
BENESCO model
(% abstinent at
1 year)
Cost of
intervention
(US$)
Unaided cessation 5.0 5.0 0
Placebo 9.3 9.3 0
NRT 15.4 15.4 405.47
Bupropion 15.9 15.4 264.40
Varenicline (12 weeks) 22.9 22.4 370.96
Varenicline (12 + 12 weeks) 27.7 — 603.89
BENESCO,Beneﬁts of Smoking Cessation on Outcomes;NRT, nicotine replacement therapy.
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Table 3 Cumulative mortality estimated from the updated BENESCO
model
Model year Lifetime
Varenicline (12 + 12 weeks)
COPD 487,696
Lung cancer 1,568,223
CHD 659,616
Stroke 417,189
Subtotal 3,132,725
Other cause 8,792,730
Total 11,925,455
Varenicline (12 weeks)
COPD 494,334
Lung cancer 1,592,214
CHD 665,133
Stroke 420,758
Subtotal 3,172,439
Other cause 8,753,016
Total 11,925,455
Bupropion
COPD 504,001
Lung cancer 1,627,151
CHD 673,166
Stroke 425,956
Subtotal 3,230,274
Other cause 8,695,181
Total 11,925,455
NRT
COPD 504,665
Lung cancer 1,629,550
CHD 673,718
Stroke 426,313
Subtotal 3,234,245
Other cause 8,691,210
Total 11,925,455
Unaided cessation
COPD 519,090
Lung cancer 1,681,680
CHD 685,704
Stroke 434,068
Subtotal 3,320,542
Other cause 8,604,913
Total 11,925,455
BENESCO, Beneﬁts of Smoking Cessation on Outcomes; CHD, coronary heart disease;
COPD, chronic obstructive pulmonary disease; NRT, nicotine replacement therapy.
Table 5 Incremental cost per QALY analysis calculated from the updated BENESCO model over the lifetime of all subjects, after discounting of 3% a
year
Intervention
Cost (Millions,
US $)
QALYs
(1000s)
Incremental costs
(Millions, US$)
Incremental
QALYs (1000s) ICER
Varenicline (12 weeks) 328,279 174,373
Varenicline (12 + 12 weeks) 328,528 174,630 249 257 $972
Bupropion 330,689 173,999 2,161 -631 Dominated
NRT 332,622 173,970 1,933 -29 Dominated
Unaided cessation 333,283 173,416 661 -554 Dominated
ICER, incremental cost-effectiveness ratio; NRT, nicotine replacement therapy; QALY, quality-adjusted life years.
Table 6 Probability of being cost-effective at various willingness to pay thresholds for 1 QALY, from the updated BENESCO model
Intervention
Willingness to pay for 1 QALY (%)
$0 $10,000 $20,000 $30,000 $40,000 $50,000
Varenicline (12 + 12 weeks) 41 67 71 73 73 73
Varenicline (12 weeks) 59 19 11 9 8 7
Bupropion 0 0 0 0 0 0
NRT 0 0 0 0 0 0
Unaided cessation 0 14 18 19 19 19
Columns may not add to 100% due to rounding.
NRT, nicotine replacement therapy; QALY, quality-adjusted life years.
Table 4 Cumulative incidence of smoking-related morbidities and
cumulative direct health costs (million US dollars) estimated from the
updated BENESCO model, after discounting at 3% a year
Model year
Lifetime cumulative
incidence of
smoking-related
morbidities
Lifetime cumulative
direct health
costs (million
US dollars)
Varenicline (12 + 12 weeks)
COPD 969,179 64,016
Lung cancer 1,702,248 48,884
CHD 1,296,450 65,882
Stroke 882,886 140,664
Asthma exacerbations 1,834,158 1,881
Total 4,850,762 321,326
Varenicline (12 weeks)
COPD 995,352 64,539
Lung cancer 1,728,442 49,731
CHD 1,308,544 66,171
Stroke 889,792 141,528
Asthma exacerbations 1,834,854 1,885
Total 4,922,130 323,855
Bupropion
COPD 1,033,467 65,302
Lung cancer 1,766,587 50,964
CHD 1,326,157 66,592
Stroke 899,848 142,787
Asthma exacerbations 1,835,867 1,892
Total 5,026,059 327,537
NRT
COPD 1,036,084 65,354
Lung cancer 1,769,207 51,048
CHD 1,327,366 66,621
Stroke 900,539 142,874
Asthma exacerbations 1,835,936 1,892
Total 5,033,196 327,789
Unaided cessation
COPD 1,092,957 66,492
Lung cancer 1,826,125 52,888
CHD 1,353,646 67,249
Stroke 915,544 144,752
Asthma exacerbations 1,837,448 1,902
Total 5,188,273 333,283
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.
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the higher purchase cost of varenicline is more than outweighed
over patients’ lifetimes by the beneﬁts gained from its higher
efﬁcacy in terms of 1-year quit rate, and the subsequent beneﬁts
in terms of smoking-related morbidity and mortality for subjects
who successfully quit smoking. This pattern of long-term cost-
effectiveness is further demonstrated by the 12 + 12-week course
of varenicline, compared with all other smoking cessation strat-
egies included in our model.
The difference between the 12 + 12 and 12-week varenicline
strategies is reﬂected in the BENESCO model inputs through a
difference in the ﬁrst year efﬁcacy (27.4% vs. 23.2%) and treat-
ment costs ($603.89 vs. $370.96). The increased efﬁcacy leads to
a higher proportion of subjects successfully quitting smoking at
the start of the model, leading to decreased risks of modeled
comorbidities throughout the subjects’ lifetimes, provided that
they do not relapse to smoking. The BENESCO model shows
that the long-term beneﬁts of smoking cessation, in the form of
decreased risks of contracting life-threatening and life-affecting
costly comorbidities, more than offset the short-term, one-off
costs of the pharmacotherapy itself. A 12 + 12-week course of
varenicline increases the chance of initial success at an acceptable
initial extra cost over a 12-week course of varenicline.
One criticism that could have been leveled at the original
BENESCO model was regarding the pooling of the efﬁcacy data
for varenicline, bupropion, and placebo: this may be regarded as
a slightly simplistic approach. This updated version of the model
now uses a mixed treatment comparison, based on the method-
ology published by Ades et al. [29], and this should be considered
as a more robust method of combining various treatment com-
parison data simultaneously in a consistent manner. The efﬁcacy
inputs for placebo, bupropion, varenicline 12, and varenicline
12 + 12 are estimated from the available clinical trial data simul-
taneously by using one internally consistent statistical model.
The efﬁcacy data for the various treatment strategies from the
original BENESCO model [8] may well be out of date now, with
other studies and publications doubtless adding to the evidence
pool. The authors acknowledge that a full update to the
BENESCO model, updating all input data in line with analysis of
the latest available information, including updated meta-analyses
of all efﬁcacy ﬁgures, would give valuable further insight in this
area. This was not, however, the purpose of this particular
update analysis.
As noted in the original BENESCO model discussions, the
perspective of the model is limited to direct treatment costs for
the interventions and the smoking-related morbidities considered
in the model. As such, other treatment and nontreatment (non-
direct) costs are not considered in the model, and this is a
standard issue with long-term smoking cessation models. This
perspective adopted by the model will therefore ignore many of
the wider economic impacts of smoking-related diseases, includ-
ing lost productivity because of ill health and early mortality, and
this exclusion biases the model against the fuller economic ben-
eﬁts of smoking cessation.
Discount rates for costs, QALYs, and life years are set at 3%,
in line with the original BENESCO model. It is recommended by
Gold et al. [30], among others, that the same rates be used for
discounting costs and beneﬁts (life years and QALYs) although
others state the case for differential discounting. There is addi-
tionally some debate as to the best value to set these ﬁgures at.
We feel that Gold’s recommendation of 3% for the base case is
still suitable for this model and it is very close to the National
Institute of Health and Clinical Excellence’s own recommenda-
tion of 3.5% [31].
An additional 12 weeks of varenicline therapy to an initial
successful 12 weeks of varenicline therapy is estimated to lead to
an increase in 1-year abstinence, from 22.9% to 27.7%, of
subjects who attempt to quit. This additional beneﬁt is consid-
ered acceptably cost-effective in comparison with a 12-week
course of varenicline, with the incremental cost-effectiveness
ratio being $972, far below a threshold of $30,000 per QALY
gained. We have not estimated a conﬁdence interval for this ratio,
which may be considered a limitation of our calculations, but we
note, as mentioned earlier, that over 70% of the probabilistic
sensitivity analysis simulations were at or below a willingness-
to-pay threshold of $30,000 per QALY, and further analysis
estimates that over 60% of simulations are at or below a thresh-
old of $5000, suggesting that the conclusion of incremental
cost-effectiveness is quite robust.
The ability of the BENESCO model to allow the incorpora-
tion of additional treatment comparisons and updated clinical
trial data, without radical changes in the results and conclusions,
shows the ﬂexibility and versatility of the underlying model
structure.
Source of ﬁnancial support: Financial support from Pﬁzer, Inc is gratefully
acknowledged.
References
1 Ezzati M, Lopez AD. Regional, disease speciﬁc patterns of
smoking-attributable mortality in 2000. Tob Control 2004;13:
388–95.
2 Eddy DM. Eddy ranks the tests. Harvard Health Letter 1992;
(Suppl.):10–1.
3 Silagy C, Lancaster T, Stead L, et al. Nicotine replacement
therapy for smoking cessation. Cochrane Database Syst Rev
2004;3:CD000146. DOI: 10.1002/14651858.CD000146.pub2.
4 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking
cessation. Cochrane Database Syst Rev 2007;31:CD000031.
5 Gonzales D, Rennard SI, Nides M, et al. Varenicline, an 42 nico-
tinic acetylcholine receptor partial agonist, vs sustained-release
bupropion and placebo for smoking cessation. JAMA 2006;
296:47–55.
6 Cahill K, Stead LF, Lancaster T. Nicotine receptor partial ago-
nists for smoking cessation. Cochrane Database Syst Rev
2007;6103:CD006103.
7 Jorenby DE, Taylor Hays J, Rigotti NA, et al. Efﬁcacy of vareni-
cline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs
placebo or sustained-release bupropion for smoking cessation.
JAMA 2006;296:56–63.
8 Howard P, Knight C, Boler A, et al. Cost-Utility analysis of
varenicline versus existing smoking cessation strategies using the
BENESCO simulation model. Pharmacoeconomics 2008;26:497–
511.
9 Varenicline for smoking cessation TA123. Technology appraisal.
July 2007. Available from: http://www.nice.org.uk/TA123
[Accessed November, 2007].
10 Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance
therapy with varenicline on smoking cessation. JAMA 2006;
296:64–71.
11 Orme ME, Hogue SL, Kennedy LM, et al. Development of the
health and economic consequences of smoking interactive model.
Tob Control 2001;10:55–61.
12 Population Division, US Census Bureau. Table 1: Annual Esti-
mates of the Population by Sex and Five-Year Age Groups for the
United States: April 1, 2000 to July 1, 2004 (NC-EST2004-01).
13 National Health Interview Survey. National Center for Health
Statistics. Available from: http://www.cdc.gov/nchs/data/nhis/
earlyrelease/200512_08.pdf [Accessed March 27, 2007].
14 Halpern M, Stanford R, Borker R. The burden of COPD in the
USA: results from the Confronting COPD survey. Respir Med
2003;97(Suppl.):S81–9.
15 Kutikova L, Bowman L, Chang S, et al. The economic burden of
lung cancer and the associated costs of treatment failure in the
United States. Lung Cancer 2005;50:143–54.
Cost-Effectiveness of 12 + 12 Weeks of Varenicline 213
16 Tsevat J, Kuntz KM, Orav EJ, et al. Cost effectiveness of pravas-
tatin therapy for survivors of myocardial infarction with average
cholesterol levels. Am Heart J 2001;141:727–34.
17 Taylor TN, Davis P, Torner JC, et al. Lifetime costs of stroke in
the United States. Stroke 1996;27:1459–66.
18 Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in
the emergency department and hospital. Am J Respir Crit Care
Med 1999;160:211–5.
19 Fleming T, ed. Redbook: Pharmacy’s Fundamental Reference
(Red Book Drug Topics). PDR: Physicians Desk Reference.
Montvale, NJ: Thomson PDR, 2005.
20 Fiscella K, Franks P. Cost effectiveness of the transdermal nico-
tine patch as an adjunct to physicians’ smoking cessation coun-
selling. JAMA 1996;275:1247–51.
21 Tengs T, Lin T. A meta-analysis of quality of life estimates for
stroke. Pharmacoeconomics 2003;21:191–200.
22 Spencer M, Briggs A, Grossman R, et al. Development of an
economic model to assess the cost effectiveness of treatment inter-
ventions for chronic obstructive pulmonary disease. Pharmaco-
economics 2005;23:619–37.
23 Mannino DM, Buist AS, Petty TL, et al. Lung function and mor-
tality in the United States: data from the First National Health
and Nutrition Examination Survey follow up study. Thorax
2003;58:388–93.
24 Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in
patients with non-small cell lung cancer. Pharmacoeconomics
2001;19:855–63.
25 Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health
Outcomes Study: initial catalogue of health-state quality factors.
Med Decis Mak Pharmacoeconomics 2005;1993:89–102. In:
Hay JW, Sterling KL, eds. Cost-effectiveness of treating low HDL-
cholesterol in the primary prevention of coronary heart disease.
Pharmacoeconomics 23:133–41.
26 Duncan PW, Lai SM, Keighley J. Deﬁning post-stroke recovery:
implications for design and interpretation of drug trials. Neuro-
pharmacology 2000;39:835–41.
27 Szende A, Svensson K, Stahl E, et al. Psychometric and utility-
based measures of health status of asthmatic patients with
different disease control level. Pharmacoeconomics 2004;22:537–
46.
28 Thun MJ, Apicella LF, Henley SJ. Smoking vs. other risk factors
as the cause of smoking-attributable deaths: confounding in the
courtroom. JAMA 2000;284:706–12.
29 Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for
evidence synthesis in cost-effectiveness analysis. Pharmacoeco-
nomics 2006;24:1–19.
30 Gold MR, Siegel JE, Russell LB, et al. Cost Effectiveness in Health
and Medicine. Oxford: Oxford University Press, 1996.
31 National Institute of Health and Clinical Excellence Guide to the
methods of technology appraisal. Available from: http://www.
nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.
pdf [Accessed March 6, 2009].
214 Knight et al.
